Skip to content

Adaptive Biotechnologies

US · ADPT #2184 by market cap Listed 2019
27.93 -0.12 -0.43%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 27.50 -1.96%
After-hours 27.89 -0.14%
Overnight 27.81 -0.86%
30.2613.8427.932026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ADPT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +40.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 7.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 74.2% Better than 86%
Operating margin -20.6% Better than 12%
Net margin -21.5% Better than 12%
Return on equity -28.2% Better than 13%
Return on invested capital -19.4% Better than 13%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 7.5% Better than 87%
6-month return 101.2% Better than 99%
12-month return (ex latest month) 37.1% Better than 75%
Distance below 52-week high 13.3% Better than 76%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.3x Better than 76%
Debt to assets 15.4% Better than 62%
Interest coverage -4.0x Better than 17%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 87.5% Better than 69%
Upside to average target 19.7% Better than 32%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -3.82%
1M +14.37%
3M +9.79%
6M +100.07%
YTD +71.98%
1Y +71.14%
3Y +529.05%
5Y +2.12%

Key statistics

Price & volume

Prev close
28.05
Open
27.43
Day range
27.15 - 28.23
Avg price
27.81
Volume
2.48M
Turnover
69.05M
Amplitude
3.83%
52-week range
12.00 - 32.21

Valuation

P/E
-71.62
P/E (TTM)
-62.07
P/B
25.65
EPS
-0.39
Net profit
-63.13M
Net assets
176.28M

Share structure

Market cap
4.52B
Float cap
3.57B
Shares out
161.88M
Float shares
127.87M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-06-27
52-week range 79% of range
12.00 32.21

13.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-37.03M net over the window

Short interest

Shares short
11.48M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Adaptive Biotechnologies (ADPT)?

Adaptive Biotechnologies last traded at 27.93. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Adaptive Biotechnologies's market cap?

About 4.52B.

What is the P/E ratio of Adaptive Biotechnologies?

The trailing twelve-month P/E is -62.07. The Valuation tab shows it against the stock's own five-year range.

Does Adaptive Biotechnologies pay a dividend?

Adaptive Biotechnologies does not currently pay a regular dividend.

Is Adaptive Biotechnologies a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 33.43, which implies 19.7% upside from the current price. This is not investment advice.

What is Adaptive Biotechnologies's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Adaptive Biotechnologies a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adaptive Biotechnologies discussion 0 comments

Add a comment